Results 161 to 170 of about 121,016 (287)

The art of tolerance [PDF]

, 1998
M Terakura, N Murase, P Aichele, PS Ohashi, RE Billingham, RM Zinkernagel, RM Zinkernagel, RM Zinkernagel, S Qian, TE Starzl, TE Starzl, Thomas Starzl, TM Kundig   +12 more
core   +1 more source

Recent patents in chimeric antigen receptors [PDF]

Nature Biotechnology, 2017
openaire   +2 more sources

Targeted Degradation of eEF2K by a Structure‐Guided PROTAC Strategy for the Treatment of Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study developed an eEF2K‐targeting PROTAC, A6, that efficiently degrades eEF2K in TNBC cells, inhibiting tumor growth in vitro and in vivo. To enhance tumor‐specific delivery, we engineered A6@ZIF‐8, a pH‐sensitive nanocarrier, which improved drug accumulation at tumor sites, offering a promising therapeutic strategy for TNBC through targeted ...
Shijun Cao, Changxin Zhong, Shilong Jiang, Yungui Li, Yang Xi, Mingxuan Xiao, Ting Jiang, Xiaoya Wan, Zonglin Chen, Xiaohui Yu, Yan Cheng   +10 more
wiley   +1 more source

Bioorthogonal Sonodynamic Plug‐and‐Play Targeting Chimeras (SDPTAC) for Precise Targeted Protein Degradation

Advanced Science, EarlyView.
Bioorthogonal SDPTAC harnesses US‐responsive Ce6‐TCO and Tz ligands via IEDDA click chemistry to assemble degraders in situ, generating ROS that selectively eliminate nuclear, cytosolic, and membrane proteins, thereby suppressing deep‐seated tumors in vivo.
Yuhan Bao, Yaojin Zhu, Xinhao Wei, Yuxin Fang, Jiayi Zhu, Fei Gao, Guoqiang Dong, Shipeng He, Chunquan Sheng   +8 more
wiley   +1 more source

PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis

Advanced Science, EarlyView.
This work introduces a study that identifies HMGCR as a novel target in TNBC and develops a light‐gated PROTAC nanomedicine. Upon irradiation, this agent selectively degrades HMGCR, reprogramming lipid metabolism to induce ferroptosis and potent antitumor immunity, thereby significantly enhancing photoimmunotherapy efficacy.
Tong Su, Guang Li, Yudong Guan, Qi Tian, Youzhi Qi, Yanqiu Zhang, Wenqian Wei, Xinxin Duan, Jiaxin Rui, Hongyan Zhu, Zengping Lin, Changchuan Xie, Zheni Xu, Yaying Wu, Xin Peng, Zhenjie Wang, Kun Chen, Xiaoyan Xin, Bing Zhang   +18 more
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

Engineering Chimeric Antigen Receptors Into Homing Missiles [PDF]

Neurosurgery, 2018
Kamil W, Nowicki, Michael P, D'Angelo, Raymond F, Sekula   +2 more
openaire   +2 more sources

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

Advanced Science, EarlyView.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao, Chengming Qu, Yanzhao Zhou, Xiaoqian Wang, Xiangjun Qian, Xun Chen, Feng Han, Xiaokai Zhang, Yiyi Ji, Han Li, ChengWei Ju, Peng Xia, Weiwei Tang, Hao Zhuang, Jinxue Zhou   +14 more
wiley   +1 more source

Mapping the experiences of adult cancer patients receiving chimeric antigen receptor T-cell (CAR-T) therapy: A scoping review protocol. [PDF]

PLoS One
Girleanu I, Brady AM, Boland V.
europepmc   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source